The metabolic spectrum of halofenate.
Halofenate is a new antilipemic drug which is an ester of carboxylic acid. In dosages ranging from 10 to 15 mg/kg, halofenate produces prominent decreases in serum triglycerides and uric acid, with only a slight reduction in serum cholesterol. The decrease in serum uric acid is due to augumented uricosuria. Halofenate is less antilipemic, but more antiuricemic than clofibrate. It apparently interferes with the protein binding of some hormones (thyroid) and drugs (tolbutamide), which can produce changes in the laboratory or clinical findings. In general, halofenate was well tolerated, except for occasional gastrointestinal symptoms.
D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000009:adverse effects / Q000494:pharmacology; D003402:Creatine Kinase / Q000097:blood; D006016:Glycolates / Q000494:pharmacology*; D006218:Halofenate / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D011339:Probenecid / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D013960:Thyroid Function Tests; D013974:Thyroxine / Q000097:blood; D014044:Tolbutamide / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D006016:Glycolates; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D014044:Tolbutamide; D003402:Creatine Kinase; D002994:Clofibrate; D006218:Halofenate; D011339:Probenecid; D013974:Thyroxine